Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6419481 | 0.80 | PTPN1 (0.47) | — | |
| SCHEMBL6849327 | 0.71 | HPGD (0.34) | ALDH1A1HPGDRECQLLMNA | |
| SCHEMBL6436181 | 0.71 | PTPN1 (0.39) | MEN1KMT2A | |
| SCHEMBL7029267 | 0.68 | KMT2A (0.33) | MEN1KMT2A | |
| SCHEMBL6849591 | 0.67 | ADORA1 (0.43) | ALDH1A1MAPTADORA1MEN1KMT2A | |
| SCHEMBL29116214 | 0.67 | ADORA1 (0.43) | ALDH1A1MAPTKDM4EADORA1RAD52 | |
| SCHEMBL6415875 | 0.64 | PTPN1 (0.50) | — | |
| SCHEMBL5420863 | 0.64 | ALDH1A1 (0.41) | ALDH1A1MAPTKDM4EADORA1RAD52 | |
| SCHEMBL2489857 | 0.61 | ALDH1A1 (0.43) | ALDH1A1MAPTKDM4EADORA1RAD52 | |
| SCHEMBL6120984 | 0.61 | ALDH1A1 (0.42) | ALDH1A1MAPTKDM4EADORA1RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404682-B1 | METHOD OF INHIBITING PTP 1B AND/OR T-CELL PTP AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK AS (DK) | 2005-09-14 | — | — | EP | disclosed |
| EP-1404682-A1 | METHOD OF INHIBITING PTP 1B AND/OR T-CELL PTP AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | Novo Nordisk A/S (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-20030064979-A1 | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | US | disclosed |
| WO-2003002569-A1 | METHOD OF INHIBITING PTP 1B AND/OR T-CELL PTP AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064979-A1 | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 | PTPRO, PTPRF, PTPA | ALDH1A1 671/4885MAPT 2025/4885KDM4E 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.